A Phase 1 interventional study of ABBV-142 and ABBV-142 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.
Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Parts:
Part 3, ONLY:
HAN CHINESE Participants:
OR
JAPANESE Participants:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ABBV-142 Dose A or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Participants will receive ABBV-142 Dose B or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Participants will receive ABBV-142 Dose C or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Participants will receive ABBV-142 Dose D or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Participants will receive ABBV-142 Dose TBD or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Participants will receive ABBV-142 Dose B or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Participants will receive ABBV-142 Dose C or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Han Chinese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Japanese participants will receive ABBV-142, dose to be determined, or Placebo on Day 1.
Drug: ABBV-142 · Drug: Placebo
Intravenous (IV) Infusion
Subcutaneous (SC) Injection
IV Infusion
SC Injection
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to Day 120
Maximum Observed Serum Concentration (Cmax) of ABBV-142
Cmax of ABBV-142 will be assessed.
Time frame: Up to Day 120
Time to Cmax (Tmax) of ABBV-142
Tmax of ABBV-142 will be assessed.
Time frame: Up to Day 120
Area Under the Serum Concentration-time Curve (AUC) of ABBV-142 from Time 0 to the Time of Last Measurable Concentration (AUCt)
AUCt of ABBV-142 will be determined.
Time frame: Up to Day 120
AUC of ABBV-142 from Time 0 to Infinity (AUCinf)
AUCinf of ABBV-142 will be assessed.
Time frame: Up to Day 120
Terminal Phase Elimination Rate Constant (β) of ABBV-142
Terminal phase elimination rate constant (β) of ABBV-142 will be assessed.
Time frame: Up to Day 120
Terminal Phase Elimination Half-life (t1/2) of ABBV-142
Terminal phase elimination half-life (t1/2) of ABBV-142 will be assessed.
Time frame: Up to Day 120
Dose Normalized Cmax of ABBV-142
Dose normalized Cmax of ABBV-142 will be assessed.
Time frame: Up to Day 120
Dose Normalized AUC of ABBV-142
Dose normalized AUC of ABBV-142 will be assessed.
Time frame: Up to Day 120
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Apr 2026, 14 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.